Elizabeth Yeu Lin - Jun 24, 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Director
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Stock symbol: TARS
Transactions as of: Jun 24, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/25/2024, 06:24 PM
Previous filing: Jun 24, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+3.35K	+167.5%		5.35K	Jun 24, 2024	Direct	F1
holding	TARS	Common Stock						12K	Jun 24, 2024	By 401(k) Plan
holding	TARS	Common Stock						15.9K	Jun 24, 2024	By Spouse's Roth IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Restricted Stock Units	Options Exercise	$0	-3.35K	-100%	$0.00^*	0	Jun 24, 2024	Common Stock	3.35K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2	Each RSU represents a contingent right to receive one share of the Company's common stock.
F3	RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.